Restricted accessResearch articleFirst published online 2026
Impact of gastric acid suppressants on oral protein kinase inhibitor efficacy: A systematic review and meta-analysis of plasma concentrations and survival outcomes
While the co-administration of oral protein kinase inhibitors (PKIs) and gastric acid suppressants (GASs) is widespread, the impact of GASs on the pharmacokinetics and survival outcomes of PKIs has remained systematically uninvestigated. The present study aimed to address this knowledge gap and to verify whether PKI plasma concentrations can predict these interactions.
Methods
MEDLINE and CENTRAL databases were searched until April 4, 2025. We included studies of PKIs where their plasma concentrations and the survival outcomes of participants taking PKIs with GASs. All studies eligible for this analysis were assessed using the appropriate risk-of-bias tool. For the meta-analysis, we estimated the ratio of the mean plasma concentrations and the hazard ratios of survival outcomes.
Results
This meta-analysis included 17,339 participants from 38 studies, including 11 PKIs. Our results revealed that the co-administration of PKIs with GASs led to a concurrent decrease in plasma concentrations and a shorter OS in 8 out of 11 PKIs, as well as a shorter PFS in 10 PKIs.
Conclusions
We found that changes in the plasma concentrations of PKIs administered with GASs could predict the changes in survival outcomes in cancer patients. One major limitation of this meta-analysis was that 68% of the eligible studies had a retrospective design.
ChoueiriTKEscudierBPowlesT, et al.Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med2015; 373: 1814–1823.
2.
ChoueiriTKHesselCHalabiS, et al.Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (alliance A031203 CABOSUN randomised trial): progression-free survival by independent review and overall survival update. Eur J Cancer2018; 94: 115–125.
3.
SmelickGSHeffronTPChuL, et al.Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development. Mol Pharm2013; 10: 4055–4062.
4.
Van LeeuwenRWvan GelderTMathijssenRH, et al.Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective. Lancet Oncol2014; 15: e315–e326.
5.
EleyTLuoFRAgrawalS, et al.Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects. J Clin Pharmacol2009; 49: 700–709.
6.
WidmerNDecosterdLALeyvrazS, et al.Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability. Br J Cancer2008; 98: 1633–1640.
7.
SoulieresDSenzerNNVokesEE, et al.Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol2004; 22: 77–85.
8.
HiltonJFTuDSeymourL, et al.An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib. Lung Cancer2013; 82: 136–142.
9.
NguyenLHollandJMamelokR, et al.Evaluation of the effect of food and gastric pH on the single-dose pharmacokinetics of cabozantinib in healthy adult subjects. J Clin Pharmacol2015; 55: 1293–1302.
10.
ButiSTommasiCScartabellatiG, et al.The impact of proton-pump inhibitors administered with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma. Anticancer Drugs2023; 34: 178–186.
11.
IndiniAPetrelliFTomaselloG, et al.Impact of use of gastric-acid suppressants and oral anti-cancer agents on survival outcomes: a systematic review and meta-analysis. Cancers (Basel)2020; 12: 998.
12.
SimWJainSRLimWH, et al.Interactions between epidermal growth factor receptor tyrosine kinase inhibitors and proton-pump inhibitors/histamine type-2 receptor antagonists in non-small cell lung cancer: a systematic review and meta-analysis. Transl Lung Cancer Res2021; 10: 3567–3581.
13.
SongHJRhewKLeeYJ, et al.Acid-suppressive agents and survival outcomes in patients with cancer: a systematic review and meta-analysis. Int J Clin Oncol2021; 26: 34–50.
14.
WeiNZhengBQueW, et al.The association between proton pump inhibitor use and systemic anti-tumour therapy on survival outcomes in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis. Br J Clin Pharmacol2022; 88: 3052–3063.
15.
XiaJZhuJLiL, et al.Concomitant gastric acid suppressants on the survival of patients with non-small-cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors: a meta-analysis. Int J Clin Pract2022; 2022: 3102641.
16.
ChangYCSongJChangY, et al.The association between proton pump inhibitors and the effectiveness of CDK inhibitors in HR+/HER- advanced breast cancer patients: a systematic review and meta-analysis. Cancers (Basel)2023; 15: 5133.
17.
De MoraesFCAPereiraCRMSanoVKT, et al.Do proton pump inhibitors affect the effectiveness of cyclin-dependent kinase 4/6 inhibitors in advanced HR positive, HER2 negative breast cancer? A meta-analysis. Front Pharmacol2024; 15: 1352224.
18.
KimBKSeongYSKwakSH, et al.Optimizing epidermal growth factor receptor-tyrosine kinase inhibitor treatment in lung cancer: a systematic review and meta-analysis of the influence of gastric acid suppressants. Transl Lung Cancer Res2024; 13: 2934–2946.
19.
GuoZZhuZLuoM, et al.Efficacy of cyclin-dependent kinase inhibitors with concurrent proton pump inhibitors in patients with breast cancer: a systematic review and meta-analysis. Oncologist2025; 30: oyae320.
20.
PageMJMcKenzieJEBossuytPM, et al.The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Br Med J2021; 372: n71.
21.
GrahamDYTanselA. Interchangeable use of proton pump inhibitors based on relative potency. Clin Gastroenterol Hepatol2018; 16: 800–808.
22.
HigginsJPTSavovićJPageMJ. Chapter 8: Assessing risk of bias in a randomized trial. In: HigginsJThomasJChandlerJ, et al. (eds) Cochrane handbook for systematic reviews of interventions. Chichester, West Sussex, UK: John Wiley & Sons, 2024Version 6.5, https://training.cochrane.org/handbook/current/chapter-08 (2024, accessed 5 June 2025).
EggerMDavey SmithGSchneiderM, et al.Bias in meta-analysis detected by a simple, graphical test. Br Med J1997; 315: 629–634.
25.
PageMJHigginsJPTSterneJAC. Chapter 13: Assessing risk of bias due to missing results in a synthesis. In: HigginsJThomasJChandlerJ, et al. (eds) Cochrane handbook for systematic reviews of interventions. Chichester, West Sussex, UK: John Wiley & Sons, 2024Version 6.5, https://training.cochrane.org/handbook/current/chapter-13 (2024, accessed 5 June 2025).
26.
SterneJASuttonAJIoannidisJP, et al.Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. Br Med J2011; 343: d4002.
27.
EgorinMJShahDDChristnerSM, et al.Effect of a proton pump inhibitor on the pharmacokinetics of imatinib. Br J Clin Pharmacol2009; 68: 370–374.
28.
KochKMImYHKimSB, et al.Effects of esomeprazole on the pharmacokinetics of lapatinib in breast cancer patients. Clin Pharmacol Drug Dev2013; 2: 336–341.
29.
TanARGibbonDGSteinMN, et al.Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors. Cancer Chemother Pharmacol2013; 71: 1635–1643.
30.
KletzlHGiraudonMDucrayPS, et al.Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals: omeprazole and ranitidine. Anticancer Drugs2015; 26: 565–572.
31.
Ruiz-GarciaAMastersJCMendes da CostaL, et al.Effect of food or proton pump inhibitor treatment on the bioavailability of dacomitinib in healthy volunteers. J Clin Pharmacol2016; 56: 223–230.
32.
SunWKlamerusKJYuhasLM, et al.Impact of acid-reducing agents on the pharmacokinetics of palbociclib, a weak base with pH-dependent solubility, with different food intake conditions. Clin Pharmacol Drug Dev2017; 6: 614–626.
33.
TangWTomkinsonHMassonE. Effect of sustained elevated gastric pH levels on gefitinib exposure. Clin Pharmacol Drug Dev2017; 6: 517–523.
34.
YokotaHSatoKOkudaY, et al.Effects of histamine 2-receptor antagonists and proton pump inhibitors on the pharmacokinetics of gefitinib in patients with non-small-cell lung cancer. Clin Lung Cancer2017; 18: e433–e439.
35.
SamantTSDhuriaSLuY, et al.Ribociclib bioavailability is not affected by gastric pH changes or food intake: in silico and clinical evaluations. Clin Pharmacol Ther2018; 104: 374–383.
36.
VishwanathanKDickinsonPABuiK, et al.The effect of food or omeprazole on the pharmacokinetics of osimertinib in patients with non-small-cell lung cancer and in healthy volunteers. J Clin Pharmacol2018; 58: 474–484.
37.
VeermanGDMHussaartsKPericR, et al.Influence of cow's milk and esomeprazole on the absorption of erlotinib: a randomized, crossover pharmacokinetic study in lung cancer patients. Clin Pharmacokinet2021; 60: 69–77.
38.
VeermanGDMHurkmansDPPaatsMS, et al.Influence of esomeprazole on the bioavailability of Afatinib: a pharmacokinetic cross-over study in patients with non-small cell lung cancer. Biomed Pharmacother2022; 155: 113695.
39.
ChuMPGhoshSChambersCR, et al.Gastric acid suppression is associated with decreased erlotinib efficacy in non-small-cell lung cancer. Clin Lung Cancer2015; 16: 33–39.
40.
LamLHCapparelliEVKurzrockR. Association of concurrent acid-suppression therapy with survival outcomes and adverse event incidence in oncology patients receiving erlotinib. Cancer Chemother Pharmacol2016; 78: 427–432.
41.
ChuMPHechtJRSlamonD, et al.Association of proton pump inhibitors and capecitabine efficacy in advanced gastroesophageal cancer: secondary analysis of the TRIO-013/LOGiC randomized clinical trial. JAMA Oncol2017; 3: 767–773.
42.
McAlisterRKAstonJPollackM, et al.Effect of concomitant pH-elevating medications with pazopanib on progression-free survival and overall survival in patients with metastatic renal cell carcinoma. Oncologist2018; 23: 686–692.
43.
FangYHYangYHHsiehMJ, et al.Concurrent proton-pump inhibitors increase risk of death for lung cancer patients receiving 1st-line gefitinib treatment - a nationwide population-based study. Cancer Manag Res2019; 11: 8539–8546.
44.
MirOTouatiNLiaM, et al.Impact of concomitant administration of gastric acid-suppressive agents and pazopanib on outcomes in soft-tissue sarcoma patients treated within the EORTC 62043/62072 trials. Clin Cancer Res2019; 25: 1479–1485.
45.
PisanoSGHoffmanSELegastoCS, et al.Effect of acid-suppressive strategies on pazopanib efficacy in patients with soft-tissue sarcoma. Clin Transl Sci2019; 12: 529–533.
46.
SharmaMHolmesHMMehtaHB, et al.The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer. Cancer2019; 125: 1155–1162.
47.
Van De SijpeGBeuselinckBVan NieuwenhuyseT, et al.Impact of concomitant acid suppressive therapy on pazopanib efficacy and dose reductions in patients with metastatic renal cell carcinoma. Eur J Clin Pharmacol2020; 76: 1273–1280.
48.
Del ReMOmariniCDiodatiL, et al.Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. ESMO Open2021; 6: 100231.
49.
LiJNickensDWilnerK, et al.Evaluation of the effect of proton pump inhibitors on the efficacy of dacomitinib and gefitinib in patients with advanced non-small cell lung cancer and EGFR-activating mutations. Oncol Ther2021; 9: 525–539.
50.
RassyECerboneLAuclinE, et al.The effect of concomitant proton pump inhibitor and cabozantinib on the outcomes of patients with metastatic renal cell carcinoma. Oncologist2021; 26: 389–396.
51.
SaitoYTakekumaYKobayashiM, et al.Impact of histamine type-2 receptor antagonists on the anticancer efficacy of gefitinib in patients with non-small cell lung cancer. Eur J Clin Pharmacol2021; 77: 381–388.
52.
EserKOnderAHSezerE, et al.Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational study. BMC Cancer2022; 22: 516.
53.
HoMCChungYSLinYC, et al.Combination use of first-line Afatinib and proton-pump inhibitors reduces overall survival among patients with EGFFR mutant lung cancer. Onco Targets Ther2022; 15: 1573–1582.
54.
LeeCHShenMCTsaiMJ, et al.Proton pump inhibitors reduce the survival of advanced lung cancer patients with therapy of gefitinib or erlotinib. Sci Rep2022; 12: 7002.
55.
Moreau-BachelardCLetailleurVBompasE, et al.Effect of concomitant proton pump inhibitors with pazopanib on cancer patients: a retrospective analysis. Cancers (Basel)2022; 14: 4721.
56.
LeeJEKwonSHKwonS, et al.Concomitant use of proton pump inhibitors and palbociclib among patients with breast cancer. JAMA Netw Open2023; 6: e2324852.
57.
OdabasHDoganAOzcelikM, et al.Does proton pump inhibitors decrease the efficacy of palbociclib and ribociclib in patients with metastatic breast cancer?Medicina (Kaunas)2023; 59: 557.
58.
Del ReMCrucittaSBrighiN, et al.Concomitant administration of VEGFR tyrosine kinase and proton pump inhibitors may impair clinical outcome of patients with metastatic renal cancer. Clin Genitourin Cancer2024; 22: 102147.
59.
Di CosimoSPerez-GarciaJMBelletM, et al.Impact of coadministration of proton-pump inhibitors and palbociclib in hormone receptor-positive/HER2-negative advanced breast cancer. Breast2024; 76: 103761.
60.
UryuKImamuraYShimoyamaR, et al.Prognostic impact of concomitant pH-regulating drugs in patients with non-small cell lung cancer receiving epidermal growth factor receptor tyrosine kinase inhibitors: the tokushukai REAl-world data project 01-S1. Cancer Chemother Pharmacol2024; 94: 197–208.
61.
AgostinettoEPfeilerGHlauschekD, et al.Drug-drug interactions between palbociclib and proton pump inhibitors in early breast cancer: an exploratory analysis of PALLAS (ABCSG-42/AFT-05/BIG-14-13/PrE0109). ESMO Open2025; 10: 104096.
62.
van ErpNPGelderblomHGuchelaarHJ. Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev2009; 35: 692–706.
63.
DickinsonPACantariniMVCollierJ, et al.Metabolic disposition of osimertinib in rats, dogs, and humans: insights into a drug designed to bind covalently to a cysteine residue of epidermal growth factor receptor. Drug Metab Dispos2016; 44: 1201–1212.
64.
GayCTouletDLe CorreP. Pharmacokinetic drug-drug interactions of tyrosine kinase inhibitors: a focus on cytochrome P450, transporters, and acid suppression therapy. Hematol Oncol2017; 35: 259–280.
65.
ZhuZZhuQ. Differences in metabolic transport and resistance mechanisms of abemaciclib, palbociclib, and ribociclib. Front Pharmacol2023; 14: 1212986.
LauritsenKLaursenLSRask-MadsenJ. Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (part I). Clin Pharmacokinet1990; 19: 11–31.
69.
HumphriesTJMerrittGJ. Review article: drug interactions with agents used to treat acid-related diseases. Aliment Pharmacol Ther1999; 13: 18–26.
70.
ZvyagaTChangSYChenC, et al.Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19. Drug Metab Dispos2012; 40: 1698–1711.
71.
PatelDBertzRRenS, et al.A systematic review of gastric acid-reducing agent-mediated drug-drug interactions with orally administered medications. Clin Pharmacokinet2020; 59: 447–462.
SuzukiKDokiKHommaM, et al.Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol2009; 67: 44–49.
75.
NarumiKSatoYKobayashiM, et al.Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: evaluation of drug-drug interactions mediated by organic anion transporter 3. Biopharm Drug Dispos2017; 38: 501–508.
76.
XiaoYXuWNiuD, et al.Investigation into the impact of proton pump inhibitors on sertraline transport across the blood-brain barrier. Eur J Pharm Sci2024; 194: 106653.
77.
MangoniAAJacksonSH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol2004; 57: 6–14.
78.
RobertsJAPeaFLipmanJ. The clinical relevance of plasma protein binding changes. Clin Pharmacokinet2013; 52: 1–8.
79.
TrobecKKerec KosMvon HaehlingS, et al.Pharmacokinetics of drugs in cachectic patients: a systematic review. PLoS One2013; 8: e79603.
AbbasRLeisterCSonnichsenD. A clinical study to examine the potential effect of lansoprazole on the pharmacokinetics of bosutinib when administered concomitantly to healthy subjects. Clin Drug Investig2013; 33: 589–595.
DuPontHLFormalSBHornickRB, et al.Pathogenesis of Escherichia coli diarrhea. N Engl J Med1971; 285: 1–9.
87.
LacySAMilesDRNguyenLT. Clinical pharmacokinetics and pharmacodynamics of cabozantinib. Clin Pharmacokinet2017; 56: 477–491.
88.
KumarakulasingheNBSynNSoonYY, et al.EGFR Kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction. Oncotarget2016; 7: 85542–85550.
89.
SalonenMAantaaEAaltonenL, et al.Importance of the interaction of midazolam and cimetidine. Acta Pharmacol Toxicol (Copenh)1986; 58: 91–95.
90.
MartínezCAlbetCAgúndezJA, et al.Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. Clin Pharmacol Ther1999; 65: 369–376.
